A Phase 1 Study of PRT1419 in People with Recurrent or Persistent Blood Cancers


Full Title

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection in Patients with Relapsed/Refractory Hematologic Malignancies


In this study, researchers are finding the highest dose of the investigational drug PRT1419 that can be given safely in people with blood cancers that have come back or continued to grow despite treatment. PRT1419 blocks MCL1, a protein that is very active in cancer cells and promotes cancer cell growth. By blocking MCL1, cancer cells may die. PRT1419 is given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participant must have acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), or MDS/myeloproliferative neoplasms (MPN) overlap syndrome that has come back or continued to grow despite treatment.
  • The serious side effects of prior therapies should go away before PRT1419 is given.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Aaron Goldberg at 646-608-3752.





Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID